Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vir Biotechnology Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Vir Biotechnology Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Jun 2021 | Lorem |
| Trial that pits COVID-19 monoclonal antibodies to weigh efficacy signals recruits 1,500 participants, with an interim analysis expected shortly, investigator says | 08 Jun 2021 | Manasi Vaidya |
| AstraZeneca's and Regeneron’s mAbs for COVID-19 prophylaxis likely to capitalize on need in immunocompromised population and deep administration gaps left by IV COVID-19 mAb therapies, experts say | 03 Jun 2021 | Manasi Vaidya |
| NIH’s inpatient ACTIV-3 COVID-19 trial plans to add another mAb in few weeks, DSMB decision on futility analysis on mAbs by GSK/Vir and Brii expected in February, sources say | 29 Jan 2021 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer